{"id":58603,"date":"2024-02-27T18:46:43","date_gmt":"2024-02-27T18:46:43","guid":{"rendered":"https:\/\/medsname.com\/olanzoop\/"},"modified":"2026-04-30T10:24:11","modified_gmt":"2026-04-30T10:24:11","slug":"olanzoop","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/olanzoop\/","title":{"rendered":"Olanzoop"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Hurtigt svar<\/h3>\n

Olanzoop (Olanzapine 5 \/ 10 mg) is an atypical antipsychotic for schizophrenia, bipolar mania and maintenance, treatment-resistant depression (with fluoxetine), and acute agitation. The most robust antipsychotic effect of the atypicals \u2014 but the heaviest metabolic burden.<\/p>\n<\/div>\n

\nHvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Olanzoop at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20-hverdages leveringsvindue eller vi gensender uden ekstra omkostninger \u2014 og kvalificerer sig til vores kundeloyalitetsprogram<\/a>. Verdensomsp\u00e6ndende forsendelse er tilg\u00e6ngelig til de fleste destinationer.<\/p>\n

What Olanzoop is and how it works<\/h2>\n

Olanzoop is an olanzapine tablet supplied by Cipla. Available strengths: 5 \/ 10 mg<\/strong>. Olanzapine is a thienobenzodiazepine atypical antipsychotic with strong D2 antagonism, strong 5-HT2A antagonism, and substantial H1 (sedation, weight gain), M1 (anticholinergic), and \u03b11 (orthostasis) blockade. The H1+M1 receptor profile is responsible both for its calming\/sedative effect (useful in acute agitation) and for its metabolic burden.<\/p>\n

Indikationer og dosering<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikation<\/th>\nStartdosis<\/th>\nM\u00e5ldosis<\/th>\nMaksimal dosis<\/th>\n<\/tr>\n<\/thead>\n
Skizofreni (voksen)<\/td>\n5\u201310 mg \u00e9n gang dagligt<\/td>\n10\u201320 mg \u00e9n gang dagligt<\/td>\n20 mg<\/td>\n<\/tr>\n
Skizofreni (ungdom \u2265 13 \u00e5r)<\/td>\n2.5\u20135 mg OD<\/td>\n10 mg \u00e9n gang dagligt<\/td>\n20 mg<\/td>\n<\/tr>\n
Bipolar mani (voksen)<\/td>\n10\u201315 mg \u00e9n gang dagligt<\/td>\n10\u201320 mg \u00e9n gang dagligt<\/td>\n20 mg<\/td>\n<\/tr>\n
Acute agitation (IM)<\/td>\n10 mg IM<\/td>\n\u2014<\/td>\n3 doser\/24 timer<\/td>\n<\/tr>\n
Treatment-resistant depression (with fluoxetine)<\/td>\n5 mg + 20 mg fluoxetine<\/td>\n5\u201318 mg<\/td>\n18 mg<\/td>\n<\/tr>\n
\u00c6ldre voksne<\/td>\n2.5\u20135 mg OD<\/td>\n5\u201310 mg \u00e9n gang dagligt<\/td>\nefter tolerabilitet<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Vigtige sikkerhedsovervejelser<\/h2>\n
\nFDA black-box \u2014 demensrelateret psykose<\/strong><\/p>\n

Alle atypiske antipsykotika b\u00e6rer en FDA black-box advarsel om \u00f8get d\u00f8delighed (prim\u00e6rt kardiovaskul\u00e6r og infektionsrelateret) ved brug til behandling af adf\u00e6rdsforstyrrelser hos \u00e6ldre med demens. Atypiske antipsykotika er ikke godkendt til demensrelateret psykose eller agitation.<\/strong>. Brug i denne population er off-label, sidste udvej, tidsbegr\u00e6nset og kr\u00e6ver en eksplicit risici-fordel samtale.<\/p>\n<\/div>\n

\nHeaviest metabolic burden of the atypicals<\/strong><\/p>\n

Olanzapine produces the most weight gain (typically 4\u201310 kg in the first 6 months, sometimes far more), the most insulin resistance, and the most lipid disturbance of any commonly-used antipsychotic. Patients can develop type 2 diabetes within months of initiation. Mandatory monitoring: weight at every visit; fasting glucose \/ HbA1c and fasting lipids at baseline, 12 weeks, then 6-monthly.<\/strong> Counsel about diet and exercise from initiation.<\/p>\n<\/div>\n

\nSedation and anticholinergic burden<\/strong><\/p>\n

Strong sedation in the first 1\u20132 weeks. Anticholinergic effects (dry mouth, constipation, urinary hesitancy) are universal. Both lessen but do not disappear.<\/p>\n<\/div>\n

\nOlanzapine + benzodiazepine IM \u2014 caution<\/strong><\/p>\n

Combining IM olanzapine with parenteral benzodiazepines has produced cases of severe hypotension, respiratory depression, and death. If both are clinically necessary in acute agitation, separate by \u2265 1 hour and monitor closely.<\/p>\n<\/div>\n

Almindelige bivirkninger<\/h2>\n